TriSalus Life Sciences Reports 57.4% Revenue Growth but Faces $41.3 Million Net Loss in Latest Quarter

TriSalus Life Sciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated revenue of $11.6 million for the third quarter, marking a 57.4% increase from $7.3 million in the same period last year. For the nine months ended September 30, 2025, total revenue reached $31.9 million, a 50.9% increase compared to $21.2 million in the prior year. Despite this growth, TriSalus reported a net loss of $41.3 million for the quarter, which includes a substantial conversion inducement related to its Series A Preferred Stock, contributing to a net loss attributable to common stockholders of $59.9 million for the nine-month period.

The company’s operating expenses also saw notable changes, with research and development costs increasing by 22.7% to $5.2 million in the third quarter, primarily due to clinical trial expenses related to its investigational drug, nelitolimod. Sales and marketing expenses rose by 11.4% to $6.8 million, reflecting increased performance-related compensation. General and administrative expenses surged by 40.9% to $6.7 million, largely due to accelerated stock-based compensation awards. Overall, the loss from operations for the third quarter was $9 million, slightly higher than the $8.7 million loss reported in the same quarter of 2024.

TriSalus has made strategic advancements, including the launch of new products such as the TriNav LV Infusion System and TriGuide Guiding Catheter, aimed at enhancing therapeutic delivery for patients with larger vessels. The company also initiated a registry study called PROTECT, which is expected to expand its market reach significantly. As of September 30, 2025, TriSalus had 49,891,299 shares of common stock outstanding, reflecting a substantial increase from the previous year due to the conversion of preferred stock.

The company’s financial position remains precarious, with total liabilities of $63.2 million against total assets of $36.5 million, resulting in a stockholders' deficit of $26.7 million. TriSalus has indicated that it may need to raise additional capital to sustain operations and fund its growth strategy, particularly as it continues to incur significant losses. The company has expressed concerns about its ability to continue as a going concern, emphasizing the need for further financing through equity or debt offerings, collaborations, or strategic alliances.

Looking ahead, TriSalus aims to leverage its innovative technologies and product offerings to capture a larger share of the oncology market. The company is focused on enhancing the adoption of its TriNav system and advancing the clinical development of nelitolimod, while also navigating the challenges posed by market conditions and the need for ongoing capital investment.